{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:12:07Z","timestamp":1792015927264,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clnesp.2020.11.018","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T06:19:43Z","timestamp":1608877183000},"page":"293-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study"],"prefix":"10.1016","volume":"41","author":[{"given":"Jerry","family":"Vockley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-5102","authenticated-orcid":false,"given":"Megan","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunming","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2020.11.018_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10545-012-9542-6","article-title":"Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients","volume":"36","author":"Baruteau","year":"2013","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s10545-009-1125-9","article-title":"Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-6-44","article-title":"Efficacy and outcome of expanded newborn screening for metabolic diseases - report of 10 years from South-West Germany","volume":"6","author":"Lindner","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ymgme.2015.10.005","article-title":"Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: review of 15 years experience","volume":"116","author":"Roe","year":"2015","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.clnesp.2020.11.018_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10545-009-1126-8","article-title":"Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1023\/A:1005556207210","article-title":"Recognition and management of fatty acid oxidation defects: a series of 107 patients","volume":"22","author":"Saudubray","year":"1999","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ymgme.2006.08.002","article-title":"Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency","volume":"90","author":"Gillingham","year":"2007","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.clnesp.2020.11.018_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1172\/JCI0215311","article-title":"Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride","volume":"110","author":"Roe","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clnesp.2020.11.018_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10545-006-0290-3","article-title":"Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential","volume":"29","author":"Roe","year":"2006","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jimd.12038","article-title":"Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD)","volume":"42","author":"Vockley","year":"2019","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2020.11.018_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ymgme.2017.02.005","article-title":"UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24 weeks of treatment","volume":"120","author":"Vockley","year":"2017","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.clnesp.2020.11.018_bib12","series-title":"Nutrition management of inherited metabolic diseases: lessons from metabolic university","article-title":"Nutrition management of fatty acid oxidation disorders","author":"Rohr","year":"2015"},{"key":"10.1016\/j.clnesp.2020.11.018_bib13","series-title":"Very long chain acyl CoA dehydrogenase deficiency (VLCADD)","author":"Rohr","year":"2008"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457720310950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457720310950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:00:43Z","timestamp":1762498843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457720310950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":13,"alternative-id":["S2405457720310950"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2020.11.018","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2020.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}]}}